Table 4 Comparison of median and interquartile range of plasma efavirenz (EFV) concentrations (mg/L) between patients treated with EFV based HAART only (EFV only) versus TB-HIV coinfected patients treated with EFV based HAART plus RIF based TB therapy (EFV + RIF) stratified by observed neuropsychiatric symptoms during therapy (Yes) and who did not (No) during therapy

15

2.29 (1.41-2.88)

22

1.48 (1.15-1.88)

41

2.6 (2.09-2.94)

84

1.97 (1.38-2.91)

13

2.25 (1.84-2.69)

15

1.53 (1.28-1.97)

39

2.47 (2.09-3.23)

41

1.9 (1.34-2.61)

15

1.9 (1.27-2.3)

25

1.66 (1.36-2.11)

37

2.51 (1.84-3.43)

74

2.05 (1.4-2.67)

12

1.64 (1.46-2.43)

28

1.57 (1.19-2.17)

36

2.65 (2.05-3.56)

74

2.37 (1.55-3.57)

12

2.11 (1.46-3.41)

24

1.77 (1.37-2.02)

25

2.43 (1.94-3.51)

61

2.17 (1.66-4.63)

14

1.69 (1.41-2.49)

31

1.56 (1.34-3.05)

35

2.48 (2.23-3.13)

86

1.91 (1.48-3.22)

12

1.86 (1.45-2.26)

29

1.84 (1.45-2.7)

31

2.61 (2.04-4.09)

70

2.29 (1.56-4.45)